Matrix metalloproteinase-2/-9 inhibitor for the treatment of ALS
Ended Project Grant Awarded Last action
- Award ID
- R43NS110077
- Recipient
-
Aquilus Pharmaceuticals, Inc. UEI EM9ULMXK5F21
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $457,639
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Originally
- Funding
-
- $457,638.96 Federal
- -$0.02 Non-federal
- Place of performance
- Woburn, MA 01801, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$0 | $0 | |
| Amendment | -$0 | -$0 | |
| Original award | $457,639 | $0 |
Quick answers
Who received award R43NS110077?
R43NS110077 was awarded to Aquilus Pharmaceuticals, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 15, 2019.
How much is award R43NS110077 worth?
$457,639 has been obligated on R43NS110077: $457,639 in federal funding and -$0 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award